Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S1 in Advanced Non-squamous Head and Neck Cancer
NCT02943252Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in head and neck cancer (HNC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT02943252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943252.